基于MRI的前列腺癌评估中ADC与ADCratio的诊断性能:一项系统评价与Meta分析
该系统评价与Meta分析纳入13项研究共1038例患者、1441个病灶,评估ADC与ADCratio对前列腺癌的诊断性能。ADC汇总敏感度80%、特异度78%,ADCratio分别为80%和80%,两者AUC均为0.86。亚组分析显示ADCratio在同时纳入外周带与移行带病灶时诊断性能优于ADC,而ADC在外周带病灶评估中性能更优。
要点
- ADC与ADCratio对前列腺癌诊断性能相当,汇总AUC均为0.86。
- ADCratio在同时纳入外周带与移行带病灶时AUC(0.87)高于ADC(0.82)。
- ADC在外周带病灶评估中诊断性能优于ADCratio。
核心结论
- ADC与ADCratio两种影像生物标志物对前列腺癌诊断均表现出良好且相当的诊断性能,但ADCratio在诊断移行带癌时性能优于ADC,ADC在外周带病灶评估中性能更优。
研究设计与样本
- 系统评价与Meta分析,检索Embase、Medline和Web of Science,纳入13项研究共1038例患者、1441个病灶,使用组织病理学参考标准作为金标准,采用双变量混合效应模型汇总AUC。
诊断标准与关键数值
- ADC汇总敏感度80%(95%CI:74-85%),特异度78%(95%CI:70-85%),AUC 0.86(95%CI:0.83-0.89)。
- ADCratio汇总敏感度80%(95%CI:74-84%),特异度80%(95%CI:71-87%),AUC 0.86(95%CI:0.83-0.89)。
- 同时纳入外周带与移行带病灶时,ADCratio AUC 0.87(95%CI:0.84-0.90),ADC AUC 0.82(95%CI:0.79-0.85)。
临床应用与阅片要点
- 在MRI定量前列腺癌诊断中,ADCratio有助于困难MRI读片时评估病灶。
- 理解定量影像生物标志物的性能有助于优化诊断性MRI方案,提高前列腺癌评估精度。
局限性
- Meta回归显示两种影像生物标志物均存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify factors influencing the diagnostic performance of the quantitative imaging biomarkers ADC and ADCratio in prostate cancer (PCa) detection.
MATERIALS AND METHODS: A systematic literature search was conducted in Embase, Medline and Web of Science, for studies evaluating ADC values and ADCratio for PCa diagnosis, using the same patient cohorts and using histopathological references as ground truth. Pooled sensitivities, specificities, summary ROC curves and AUCs were calculated from constructed contingency data tables. Diagnostic performance (AUC) was quantitatively pooled using a bivariate mixed effects model. For identifying influencing factors, subgroup analysis, publication bias and heterogeneity assessment were investigated.
RESULTS: Thirteen studies, involving 1038 patients and 1441 lesions, were included. For ADC, the pooled sensitivity and specificity was 80% (95% CI: 74-85%) and 78% (95% CI: 70-85%), respectively. For ADCratio pooled sensitivity and specificity was 80% (95% CI: 74-84%) and 80% (95% CI: 71-87%). Summary ROC analysis revealed AUCs of 0.86 (95% CI: 0.83-0.89) and 0.86 (95% CI: 0.83-0.89), respectively. Meta-regression showed heterogeneity between both imaging biomarkers. Subgroup analysis showed that ADCratio improved diagnostic performance in comparison to ADC when including both peripheral and transitional zone lesions (AUC: 0.87 [95% CI: 0.84-0.90] and 0.82 [95% CI: 0.79-0.85], respectively).
CONCLUSION: Both ADC and ADCratio imaging biomarkers showed good and comparable diagnostic performance in PCa diagnosis. However, ADCratio shows better diagnostic performance than ADC in diagnosing transition zone cancers.
CLINICAL RELEVANCE STATEMENT: In quantitative MRI-based PCa diagnosis, the imaging biomarker ADCratio is useful in challenging MRI readings of lesions. Understanding the performance of quantitative imaging biomarkers better can aid diagnostic MRI protocols, enhancing the precision of PCa assessments.
KEY POINTS: MRI diffusion-weighted imaging-based ADC and ADCratio have comparable diagnostic performance in PCa assessment. In contrast to ADC, the ADCratio improves diagnostic performance, when assessing whole gland lesions. Compared to ADCratio, the ADC demonstrates enhanced diagnostic performance when evaluating peripheral zone lesions.
引用
- Agrotis G, Pooch E, Abdelatty M, et al. Diagnostic performance of ADC and ADCratio in MRI-based prostate cancer assessment: A systematic review and meta-analysis. Eur Radiol. 2024. PMID: 38995382. doi:10.1007/s00330-024-10890-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。